Shares of medication company Viatris (NASDAQ:VTRS) jumped 3% in the morning session after it received approval from the U.S.

Viatris (VTRS) stock gains as the FDA OK its generic Iron Sucrose Injection targeting Venofer marketed by Daiichi Sankyo (DSKYF) (DSNKY) and Vifor. Read more here.

Approval is Another Milestone of Viatris' Ability to Successfully Develop Complex Generic Medicines Approval Granted with Competitive Generic Therapy ...

Investing.com -- Viatris Inc (NASDAQ: VTRS) stock rose 2.6% following the U.S. Food and Drug Administration’s approval of the company’s Iron Sucrose Injection, USP, the first generic version of ...

Viatris Inc (NASDAQ:VTRS) saw its stock increase by 2.6% after the U.S. Food and Drug Administration approved its Iron ...

Venofer was approved in the U.S. in 2000. It was developed by Vifor Pharma, which is now part of CSL Ltd. American Regent, a unit of Daiichi Sankyo, manufactures and sells it in the U.S. under a ...

Theravance Biopharma (NASDAQ:TBPH) is scheduled to announce Q2 earnings results on Tuesday, August 12th, after market close. The consensus EPS Estimate is -$0.13 (+61.8% Y/Y) and the consensus Revenue ...